Related Experiment Video

Updated: Apr 20, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

884

Pediatric acute myeloid leukemia: biology and therapeutic implications of genomic variants

Katherine Tarlock1, Soheil Meshinchi1

  • 1Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, Seattle, WA 98109, USA.

Pediatric Clinics of North America
|December 2, 2014
PubMed

Insights

Acute myeloid leukemia (AML) in children presents unique molecular and genetic profiles compared to adults. Understanding these differences is key for accurate risk stratification and targeted therapy in pediatric AML.

Area of Science:

  • Pediatric oncology
  • Molecular biology
  • Hematologic malignancies

Background:

  • Acute myeloid leukemia (AML) is a complex disease with significant molecular heterogeneity.
  • Age-associated molecular alterations create distinct signatures in younger children versus older children and adolescents with AML.
  • Pediatric AML exhibits unique genetic and epigenetic profiles compared to adult AML.

Purpose of the Study:

  • To highlight the molecular differences in pediatric AML based on age.
  • To emphasize the role of genetic and epigenetic alterations in leukemogenesis and disease evolution.
  • To underscore the importance of next-generation sequencing in understanding AML biology and identifying therapeutic targets.

Main Methods:

  • Analysis of molecular and genetic alterations in pediatric AML samples.
  • Comparison of molecular profiles between different age groups (younger children, older children, adolescents) and with adult AML.
  • Review of the impact of cytogenetic alterations, somatic mutations, and treatment response on risk stratification.

Main Results:

  • Younger children with AML show distinct molecular signatures compared to older children and adolescents.
  • Significant genetic and epigenetic differences exist between pediatric and adult AML.
  • Somatic and epigenetic alterations are crucial in myeloid leukemogenesis and evolve from diagnosis to relapse.

Conclusions:

  • Age-specific molecular profiles in pediatric AML necessitate tailored approaches.
  • Cytogenetic alterations, somatic mutations, and treatment response are critical for risk stratification and therapy allocation.
  • Next-generation sequencing advances our understanding of AML biology and aids in identifying novel therapeutic targets.

Keywords:
Acute myeloid leukemiaEpigeneticGenomicPediatricsTherapy

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

959
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

8.1K

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
74
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
108
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
142
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
4.3K